In the first two years of the Joe Biden presidency, Senator Joe Manchin has become one of big business’s favorite lawmakers, thanks to the way he stalled and ultimately killed Democrats’ Build Back Better bill, a health care and climate spending package that included the party’s signature drug pricing measure.

Now, with Manchin signaling he could support a new compromise budget bill that includes drug pricing reforms, Big Pharma isn’t taking any chances — and so it has started ramping up advertising pressure in his state. The industry is likely hoping for a repeat of Manchin’s habit of signaling support for popular initiatives like a billionaire tax, and then quickly backing down the moment moneyed interests raise objections.

Speaking to the world’s financial elites at the World Economic Forum in Davos, Switzerland, on Monday, Manchin said Congress still has “an opportunity” to pass meaningful legislation before the midterm elections — including on prescription drug prices. The statement was significant, because Manchin has long asserted that he supports some measures to reduce medicine prices.